词条 | Non-Hodgkin lymphoma |
释义 |
| name = Non-Hodgkin lymphoma | image = Mantle cell lymphoma - intermed mag.jpg | caption = Micrograph of mantle cell lymphoma, a type of non-Hodgkin lymphoma. Terminal ileum. H&E stain. | synonyms = Non-Hodgkin disease | field = Hematology and oncology | symptoms = Enlarged lymph nodes, fever, night sweats, weight loss, tiredness, itching[1] | complications = | onset = 65–75 years old[2] | duration = | causes = | risks = Poor immune function, autoimmune diseases, Helicobacter pylori infection, hepatitis C, obesity, Epstein-Barr virus infection[1][4] | diagnosis = Bone marrow or lymph node biopsy[1] | differential = | prevention = | treatment = Chemotherapy, radiation, immunotherapy, targeted therapy, stem cell transplantation, surgery, watchful waiting[1] | medication = | prognosis = Five-year survival rate 71% (USA)[2] | frequency = 4.3 million (affected during 2015)[8] | deaths = 231,400 (2015)[9] }}Non-Hodgkin lymphoma (NHL) is a group of blood cancers that includes all types of lymphoma except Hodgkin's lymphomas.[1] Symptoms include enlarged lymph nodes, fever, night sweats, weight loss and tiredness.[1] Other symptoms may include bone pain, chest pain or itchiness.[1] Some forms are slow-growing, while others are fast-growing.[1] Lymphomas are types of cancer that develop from lymphocytes, a type of white blood cell.[2] Risk factors include poor immune function, autoimmune diseases, Helicobacter pylori infection, hepatitis C, obesity and Epstein-Barr virus infection.[1][2] The World Health Organization (WHO) classifies lymphomas into five major groups, including one for Hodgkin's lymphoma.[3] Within the four groups for NHL, there are over 60 specific types of lymphoma.[4][5] Diagnosis is by examination of a bone marrow or lymph node biopsy.[1] Medical imaging is done to help with cancer staging.[1] Treatment depends on whether the lymphoma is slow- or fast-growing and if it is in one area or many areas.[1] Treatments may include chemotherapy, radiation, immunotherapy, targeted therapy, stem cell transplantation, surgery or watchful waiting.[1] If the blood becomes overly thick due to high numbers of antibodies, plasmapheresis may be used.[1] Radiation and some chemotherapy, however, increase the risk of other cancers, heart disease or nerve problems over the subsequent decades.[1] In 2015, about 4.3 million people had non-Hodgkin lymphoma, and 231,400 died.[6][7] In the United States, 2.1% of people are affected at some point in their life.[2] The most common age of diagnosis is between 65 and 75 years old.[2] The five-year survival rate in the United States is 71%.[8] Signs and symptomsThe signs and symptoms of non-Hodgkin's lymphoma vary depending upon its location within the body. Symptoms include enlarged lymph nodes, fever, night sweats, weight loss, and tiredness. Other symptoms may include bone pain, chest pain, or itchiness. Some forms are slow growing while others are fast growing.[1] Enlarged lymph nodes may cause lumps to be felt under the skin when they are close to the surface of the body. Lymphomas in the skin may also result in lumps, which are commonly itchy, red or purple. Lymphomas in the brain can cause weakness, seizures, problems with thinking and personality changes.{{mcn|date=February 2017}} CausesThe many different forms of lymphoma probably have different causes. These possible causes and associations with at least some forms of NHL include the following:
Familial componentFamilial lymphoid cancer is rare. The familial risk of lymphoma is elevated for multiple lymphoma subtypes, suggesting a shared genetic cause. However, a family history of a specific subtype is most strongly associated with risk for that subtype, indicating that these genetic factors are subtype-specific. Genome-wide association studies (GWAS) have successfully identified 67 single nucleotide polymorphisms (SNPs) from 41 loci, most of which are subtype specific.[16] HIV/AIDSThe Center for Disease Control and Prevention (CDC) included certain types of non-Hodgkin's lymphoma as AIDS-defining cancers in 1987.[17] Immune suppression rather than HIV itself is implicated in the pathogenesis of this malignancy, with a clear correlation between the degree of immune suppression and the risk of developing NHL. Additionally, other retroviruses such as HTLV may be spread by the same mechanisms that spread HIV, leading to an increased rate of co-infection.[18] The natural history of HIV infection has been greatly changed over time. As a consequence, rates of non-Hodgkin's lymphoma (NHL) in people infected with HIV has significantly declined in recent years.[19] TreatmentThe traditional treatment of NHL includes chemotherapy and stem cell transplants. The most common chemotherapy used for B-cell non-Hodgkin lymphoma is R-CHOP, which is a regiment of four drugs (cyclophosphamide, doxorubicin, vincristine, and prednisone plus rituximab).[20] There have been developments in immunotherapy. Bendamustine is also used. EpidemiologyGlobally, as of 2010, there were 210,000 deaths, up from 143,000 in 1990.[21] Rates of Non-Hodgkin lymphoma increases steadily with age.[14] Up to 45 years NHL is more common among males than females.[22] United StatesIn the US, data from 2007–2011 show that there were about 19.7 cases of NHL per 100,000 adults per year, 6.3 deaths per 100,000 adults per year. About 2.1 percent of men and women are diagnosed with NHL at some point during their lifetime, and there were around 530,919 people living with non-Hodgkin lymphoma.[23] American Cancer Society lists Non-Hodgkin lymphoma as one of the most common cancers in the United States, accounting for about 4% of all cancers[24]. CanadaIn Canada, NHL is the fifth most common cancer in males and sixth most common cancer in females. The lifetime probability of developing a lymphoid cancer is 1 in 44 for males, and 1 in 51 for females.[25] United KingdomNHL is the sixth most common cancer in the UK (around 12,800 people were diagnosed with the disease in 2011), and it is the eleventh most common cause of cancer death (around 4,700 people died in 2012).[26] HistoryWhile consensus was rapidly reached on the classification of Hodgkin lymphoma, there remained a large group of very different diseases requiring further classification. The Rappaport classification, proposed by Henry Rappaport in 1956 and 1966, became the first widely accepted classification of lymphomas other than Hodgkin. Following its publication in 1982, the Working Formulation became the standard classification for this group of diseases. It introduced the term non-Hodgkin lymphoma or NHL and defined three grades of lymphoma.{{fact|date=January 2018}} NHL consists of many different conditions that have little in common with each other. They are grouped by their aggressiveness. Less aggressive non-Hodgkin lymphomas are compatible with a long survival while more aggressive non-Hodgkin lymphomas can be rapidly fatal without treatment. Without further narrowing, the label is of limited usefulness for patients or doctors. The subtypes of lymphoma are listed there.{{fact|date=January 2018}} Nevertheless, the Working Formulation and the NHL category continue to be used by many. To this day, lymphoma statistics are compiled as Hodgkin's versus non-Hodgkin lymphomas by major cancer agencies, including the US National Cancer Institute in its SEER program, the Canadian Cancer Society and the IARC. References1. ^1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 {{cite web|title=Adult Non-Hodgkin Lymphoma Treatment (PDQ®)–Patient Version|url=http://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq#section/all|website=NCI|accessdate=13 August 2016|date=August 3, 2016|deadurl=no|archiveurl=https://web.archive.org/web/20160816021510/http://www.cancer.gov/types/lymphoma/patient/adult-nhl-treatment-pdq#section/all|archivedate=16 August 2016|df=}} 2. ^1 {{cite book|title=World Cancer Report 2014|date=2014|publisher=World Health Organization|isbn=978-9283204299|pages=Chapter 2.4, 2.6}} 3. ^{{cite web|title=Adult Non-Hodgkin Lymphoma Treatment (PDQ®)–Health Professional Version|url=http://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq#section/all|website=NCI|accessdate=13 August 2016|date=June 1, 2016|deadurl=no|archiveurl=https://web.archive.org/web/20160812081200/http://www.cancer.gov/types/lymphoma/hp/adult-nhl-treatment-pdq#section/all|archivedate=12 August 2016|df=}} 4. ^{{cite web|title=Different types of non Hodgkin lymphoma|url=http://www.cancerresearchuk.org/about-cancer/type/non-hodgkins-lymphoma/about/types/the-most-common-types-of-non-hodgkins-lymphoma|website=Cancer Research UK|accessdate=13 August 2016|deadurl=no|archiveurl=https://web.archive.org/web/20160814034909/http://www.cancerresearchuk.org/about-cancer/type/non-hodgkins-lymphoma/about/types/the-most-common-types-of-non-hodgkins-lymphoma|archivedate=14 August 2016|df=}} 5. ^{{cite book|last1=Bope|first1=Edward T.|last2=Kellerman|first2=Rick D.|title=Conn's Current Therapy 2016|date=2015|publisher=Elsevier Health Sciences|isbn=9780323355353|page=878|url=https://books.google.com/books?id=_x_mCgAAQBAJ&pg=PT914|language=en|deadurl=no|archiveurl=https://web.archive.org/web/20170910182735/https://books.google.com/books?id=_x_mCgAAQBAJ&pg=PT914|archivedate=2017-09-10|df=}} 6. ^1 {{cite journal|last1=GBD 2015 Disease and Injury Incidence and Prevalence|first1=Collaborators.|title=Global, regional, and national incidence, prevalence, and years lived with disability for 310 diseases and injuries, 1990–2015: a systematic analysis for the Global Burden of Disease Study 2015.|journal=Lancet|date=8 October 2016|volume=388|issue=10053|pages=1545–1602|pmid=27733282|doi=10.1016/S0140-6736(16)31678-6|pmc=5055577}} 7. ^1 {{cite journal|last1=GBD 2015 Mortality and Causes of Death|first1=Collaborators.|title=Global, regional, and national life expectancy, all-cause mortality, and cause-specific mortality for 249 causes of death, 1980–2015: a systematic analysis for the Global Burden of Disease Study 2015.|journal=Lancet|date=8 October 2016|volume=388|issue=10053|pages=1459–1544|pmid=27733281|doi=10.1016/s0140-6736(16)31012-1|pmc=5388903}} 8. ^1 2 3 4 5 {{cite web|title=SEER Stat Fact Sheets: Non-Hodgkin Lymphoma|url=http://seer.cancer.gov/statfacts/html/nhl.html|website=NCI|accessdate=13 August 2016|date=April 2016|deadurl=no|archiveurl=https://web.archive.org/web/20140706125600/http://www.seer.cancer.gov/statfacts/html/nhl.html|archivedate=6 July 2014|df=}} 9. ^{{cite journal |vauthors=Maeda E, Akahane M, Kiryu S, Kato N, Yoshikawa T, Hayashi N, Aoki S, Minami M, Uozaki H, Fukayama M, Ohtomo K | title = Spectrum of Epstein-Barr virus-related diseases: A pictorial review | journal = Japanese Journal of Radiology | volume = 27 | issue = 1 | pages = 4–19 | year = 2009 | pmid = 19373526 | pmc = | doi = 10.1007/s11604-008-0291-2 }} 10. ^{{cite journal |vauthors=Peveling-Oberhag J, Arcaini L, Hansmann ML, Zeuzem S | title = Hepatitis C-associated B-cell non-Hodgkin lymphomas. Epidemiology, molecular signature and clinical management | journal = Journal of Hepatology | volume = 59 | issue = 1 | pages = 169–177 | year = 2013 | pmid = 23542089 | pmc = | doi = 10.1016/j.jhep.2013.03.018}} 11. ^{{cite journal |vauthors=Kramer S, Hikel SM, Adams K, Hinds D, Moon K | title = Current Status of the Epidemiologic Evidence Linking Polychlorinated Biphenyls and Non-Hodgkin Lymphoma, and the Role of Immune Dysregulation | journal = Environmental Health Perspectives | volume = 120 | issue = 8 | pages = 1067–75 | year = 2012 | pmid = 22552995 | pmc = 3440083 | doi = 10.1289/ehp.1104652 }} 12. ^{{cite journal |vauthors=Zani C, Toninelli G, Filisetti B, Donato F | title = Polychlorinated biphenyls and cancer: an epidemiological assessment | journal = J Environ Sci Health C Environ Carcinog Ecotoxicol Rev | volume = 31 | issue = 2 | pages = 99–144 | year = 2013 | pmid = 23672403 | doi = 10.1080/10590501.2013.782174 | url = }} 13. ^{{cite journal |vauthors=Lauby-Secretan B, Loomis D, Grosse Y, El Ghissassi F, Bouvard V, Benbrahim-Tallaa L, Guha N, Baan R, Mattock H, Straif K | title = Carcinogenicity of polychlorinated biphenyls and polybrominated biphenyls | journal = Lancet Oncology | volume = 14 | issue = 4 | pages = 287–288 | year = 2013 | pmid = 23499544 | doi = 10.1016/s1470-2045(13)70104-9 }} 14. ^1 {{Cite book|title=Cancer and its Management|last=Tobias|first=J|author2=Hochhauser D.|publisher=Wiley-Blackwell|year=2015|isbn=9781118468715|edition=7th|chapter=}} 15. ^{{cite book | veditors = Kufe DW, Pollock RE, Weichselbaum RR, ((Bast RC Jr)), Gansler TS, Holland JF, ((Frei E III)) | title = Holland-Frei Cancer Medicine | author1 = Arnold S Freedman | author2 = Lee M Nadler | chapter = Chapter 130: Non–Hodgkin’s Lymphomas | edition = 5th | publisher = B.C. Decker | location = Hamilton, Ont | year = 2000 | isbn = 1-55009-113-1 | url = https://www.ncbi.nlm.nih.gov/books/NBK20925/ | deadurl = no | archiveurl = https://web.archive.org/web/20170910182735/https://www.ncbi.nlm.nih.gov/books/NBK20925/ | archivedate = 2017-09-10 | df = }} 16. ^{{cite journal|last1=Cerhan|first1=James|title=Familial predisposition and genetic risk factors for lymphoma.|journal=Blood|date=Nov 12, 2015|volume=126|issue=20|page=2267-2273|doi=10.1182/blood-2015-04-537498|pmid=26405224|pmc=4643002}} 17. ^{{cite journal | title = Revision of the CDC surveillance case definition for acquired immunodeficiency syndrome. Council of State and Territorial Epidemiologists; AIDS Program, Center for Infectious Diseases | journal = Morbidity and Mortality Weekly Report | volume = 36 | issue = Suppl 1 | pages = 1S–15S | year = 1987 | pmid = 3039334 | url = https://www.cdc.gov/mmwr/pdf/other/mmsu3601.pdf | deadurl = no | archiveurl = https://web.archive.org/web/20170609012431/https://www.cdc.gov/mmwr/pdf/other/mmsu3601.pdf | archivedate = 2017-06-09 | df = }} 18. ^{{cite journal |doi=10.2217/hiv.10.54 |title=HIV-related lymphoma |year=2010 |last1=Lee |first1=Belinda |last2=Bower |first2=Mark |last3=Newsom-Davis |first3=Thomas |last4=Nelson |first4=Mark |journal=HIV Therapy |volume=4 |issue=6 |pages=649–659}} 19. ^1 {{cite journal |vauthors=Pinzone MR, Fiorica F, Di Rosa M, Malaguarnera G, Malaguarnera L, Cacopardo B, Zanghì G, Nunnari G | title = Non-AIDS-defining cancers among HIV-infected people | journal = Eur Rev Med Pharmacol Sci | volume = 16 | issue = 10 | pages = 1377–88 | date = October 2012 | pmid = 23104654 | doi = | url = }} 20. ^{{Cite web|url=https://www.cancer.org/cancer/non-hodgkin-lymphoma/treating/b-cell-lymphoma.html|title=Treating B-Cell Non-Hodgkin Lymphoma|website=www.cancer.org|language=en|access-date=2019-02-05}} 21. ^{{cite journal|display-authors=etal|date=Dec 15, 2012|title=Global and regional mortality from 235 causes of death for 20 age groups in 1990 and 2010: a systematic analysis for the Global Burden of Disease Study 2010.|journal=Lancet|volume=380|issue=9859|pages=2095–128|doi=10.1016/S0140-6736(12)61728-0|pmid=23245604|vauthors=Lozano R, Naghavi M, Foreman K, Lim S, Shibuya K, Aboyans V, Abraham J, Adair T, Aggarwal R, Ahn SY}} 22. ^Bleyer, W Archie, Barr, Ronald D. Cancer in Adolescents and Young Adults. Springer, 2007, p. 129. 23. ^NIH NCI Surveillance, Epidemiology, and End Results Program. Posted to SEER website April 2014. SEER Stat Fact Sheets: Non-Hodgkin Lymphoma {{webarchive|url=https://web.archive.org/web/20140706125600/http://www.seer.cancer.gov/statfacts/html/nhl.html |date=2014-07-06 }} Page accessed February 26, 2015 24. ^{{Cite web|url=https://www.cancer.org/cancer/non-hodgkin-lymphoma/about/key-statistics.html|title=What Are the Key Statistics About Non-Hodgkin Lymphoma?|website=www.cancer.org|access-date=2018-01-05}} 25. ^{{Cite web|url=http://www.cancer.ca/en/cancer-information/cancer-101/canadian-cancer-statistics-publication/?region=on| title=Canadian Cancer Statistics|website=www.cancer.ca|access-date=2018-02-08}} 26. ^{{cite web|title=Non-hodgkin lymphoma statistics|url=http://www.cancerresearchuk.org/cancer-info/cancerstats/types/nhl/|website=Cancer Research UK|accessdate=28 October 2014|deadurl=no|archiveurl=https://web.archive.org/web/20141007180810/http://www.cancerresearchuk.org/cancer-info/cancerstats/types/nhl/|archivedate=7 October 2014|df=}} External links{{Medical condition classification and resources| DiseasesDB = 9065 | ICD10 = {{ICD10|C|82||c|81}}-{{ICD10|C|85||c|81}} | ICD9 = {{ICD9|200}}, {{ICD9|202}} | ICDO = 9591/3 | OMIM = 605027 | MedlinePlus = 000581 | eMedicineSubj = med | eMedicineTopic = 1363 | eMedicine_mult = {{eMedicine2|ped|1343}} | MeshID = D008228 }}
4 : Lymphoma|Hepatitis C virus-associated diseases|RTT|Non-Hodgkin lymphoma |
随便看 |
|
开放百科全书收录14589846条英语、德语、日语等多语种百科知识,基本涵盖了大多数领域的百科知识,是一部内容自由、开放的电子版国际百科全书。